Clinical Trials in San Francisco

Showing 3801-3820 of 12,991 trials

177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

NCT03805594

This phase Ib trial studies the dose and schedule of 177Lu-PSMA-617 and pembrolizumab in treating persons with castration-resistant prostate cancer that has spread to other places in the body. 177Lu-PSMA-617 carries a radioactive component which attached to the prostate specific membrane antigen (PSMA) receptor found on tumor cells. Its radiation component destroys the tumor cell. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving 177Lu-PSMA-617 and pembrolizumab may work better at treating prostate cancer.

Castration Levels of TestosteroneCastration-Resistant Prostate CarcinomaMetastatic Prostate Carcinoma+4 more

University of California, San Francisco43 participantsStarted May 2019

San Francisco, California, United States

COMPLETEDPhase 1/2< 1 mile

Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer

NCT03250676

The primary purpose of phase 1 portion of this study is to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of H3B-6545 in women with locally advanced or metastatic estrogen receptor (ER)-positive, human epidermal growth factor 2 (HER2)-negative breast cancer. The primary purpose of phase 2 portion of this study is to estimate the efficacy of H3B-6545 in terms of best overall response rate, duration of response (DoR), clinical benefit rate (CBR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS) in all participants with ER-positive, HER2-negative breast cancer and in those with and without ER alpha mutation (including a clonal estrogen receptor 1 gene \[ESR1\] Y537S mutation).

Breast NeoplasmsBreast CancerEstrogen-receptor Positive Breast Cancer+5 more

Eisai Inc.151 participantsStarted Aug 2017

Goodyear, Arizona, United States • Los Angeles, California, United States • San Francisco, California, United States +36 more locations

177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer

Find Trials by Condition in San Francisco

Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN)

Spermatogonial Differentiation Via Testicular Organoid

In-Home Technology for Caregivers of People With Dementia and Mild Cognitive Impairment: Rural Homes

Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis

[Study Evaluating the Efficacy and Safety of a Digital Therapeutic as an Adjunct to TAU in Postpartum Depression]

FUnctional diagnoSIs of corONary Stenosis (FUSION)

Long-term Follow-up of Participants With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product

Persona Partial Knee Clinical Outcomes Study

Pre-Active PD: Looking At Physical Activity Behavior Change in Parkinson's Disease

HIV Pre-Exposure Prophylaxis Among an Unrecognized Sexual Minority Population

International Kink Health Study

An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants

Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia

Dermal Allograft Augmentation of Large and Massive Rotator Cuff Tears

Comparison of Chronocort Versus Standard Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over With Congenital Adrenal Hyperplasia

Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms

TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia

Counseling for Harm Reduction and Retention in Medication-assisted Treatment - Cherokee Nation